Press Releases for ITMN

Press Releases
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
InterMune to Present at Canaccord Adams Conference
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
InterMune to Release Second Quarter Financial Results on August 6
InterMune to Present at Goldman Sachs Healthcare Conference
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
/C O R R E C T I O N -- InterMune, Inc./
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
InterMune to Release First Quarter Financial Results on April 30
InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
InterMune to Present at Canaccord Adams Hepatitis C Conference
InterMune to Present at Citi's 4th Annual Biotech Day
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
InterMune to Present at Cowen Health Care Conference
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
InterMune Announces Issuance of U.S. Patent for ITMN-191
InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
InterMune Reports Results from Triple Combination Study of ITMN-191
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
InterMune to Present at J.P. Morgan Healthcare Conference
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
InterMune to Present at Lazard Capital Markets Healthcare Conference
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
InterMune to Present at Deutsche Bank Biotech Boston Confab
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
InterMune to Release Third Quarter 2008 Financial Results on November 6
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Wall Street Media Presents Exclusive Videos from the Baird Small-Cap Healthcare Conference
InterMune to Present at Baird Small Cap Healthcare Conference
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
InterMune to Present at Thomas Weisel Partners Healthcare Conference
InterMune to Present at Canaccord Adams Conference
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
InterMune to Present at BMO Healthcare Conference
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
InterMune to Present at Jefferies Healthcare Conference
InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA - May 27 2008 12:56AM
InterMune to Present at Citigroup Healthcare Conference - May 27 2008 12:56AM
InterMune to Present at Bank of America Health Care Conference - Jun 1 2008 11:31PM
InterMune Reports First Quarter 2008 Financial Results and Business Highlights - Jun 1 2008 11:31PM
InterMune to Present at Deutsche Bank Health Care Conference
InterMune to Release First Quarter 2008 Financial Results on May 1
InterMune Announces Progress on Pirfenidone in IPF
Breaking News Alert: OCOL!
InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
BellwetherReport.com Free Analyst Review for CEGE, ITMN, ATHR and ORLY
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update